세계의 비강 백신 시장 - 산업규모, 점유율, 동향, 시장 기회, 예측, 백신 유형별, 용도별, 지역별, 경쟁별(2020-2030년)

Global Nasal Vaccines Market was valued at USD 425.20 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.05% through 2030. The global healthcare landscape is continually evolving, and one significant development in recent years is the emergence of nasal vaccines. Nasal vaccines offer a novel and effective way to protect against various infectious diseases, providing a non-invasive alternative to traditional injection-based vaccines. The global nasal vaccines market has been gaining momentum, with advancements in vaccine technology and increasing awareness of their benefits. The global nasal vaccines market has witnessed substantial growth in recent years, driven by several key factors. These include a rising demand for painless and convenient vaccination methods, increased focus on preventive healthcare, and the development of innovative nasal vaccine formulations. Nasal vaccines are particularly appealing for children and individuals who fear needles, making them a preferred choice for immunization. The market has seen the expansion of the types of vaccines delivered nasally. Initially, nasal vaccines were primarily associated with influenza vaccines, but now they cover a wider range of diseases, including COVID-19, measles, mumps, rubella, and more. This diversification has significantly boosted the market. Pharmaceutical companies and research institutions are actively investing in R&D to develop more effective and potent nasal vaccine formulations. This includes enhancing the stability and delivery mechanisms of nasal vaccines.

Governments and international organizations are increasingly recognizing the potential of nasal vaccines in improving vaccination coverage rates. This has led to greater investments in research and vaccination campaigns using nasal vaccines, particularly in low-income and middle-income countries. Public awareness campaigns and educational efforts are playing a vital role in increasing the acceptance of nasal vaccines. These campaigns highlight the advantages of nasal vaccines, such as reduced pain, easier administration, and quicker immunity development.

Ky Market Drivers

Growing Prevalence of Infectious and Respiratory Diseases

The rising incidence of infectious and respiratory diseases is a key driver fueling the expansion of the global nasal vaccines market. As the global burden of diseases such as influenza, COVID-19, tuberculosis (TB), and respiratory syncytial virus (RSV) continues to escalate, there is an increasing demand for effective, accessible, and non-invasive vaccination solutions. The global healthcare sector faces significant challenges due to the widespread prevalence of seasonal influenza and tuberculosis (TB). Each year, seasonal influenza affects approximately one billion people worldwide, with 3 to 5 million cases progressing to severe illness. The disease is responsible for an estimated 290,000 to 650,000 respiratory-related deaths annually, creating substantial strain on healthcare systems and economic productivity.

Similarly, tuberculosis (TB) remains a critical global health challenge. In 2023 alone, an estimated 10.8 million people contracted TB worldwide, affecting 6.0 million men, 3.6 million women, and 1.3 million children. The disease continues to impact all countries and age groups, reinforcing its widespread public health burden. Despite being both curable and preventable, TB persists due to gaps in early detection, treatment access, and healthcare infrastructure. Nasal vaccines provide a targeted immune response, particularly against airborne pathogens, making them a highly attractive alternative to traditional injectable vaccines. Respiratory diseases are among the leading causes of morbidity and mortality worldwide. Influenza alone affects millions annually, leading to hospitalizations, economic strain, and loss of productivity. Similarly, emerging infectious diseases like COVID-19 have reinforced the need for scalable and easily deployable vaccination strategies. In 2020, chronic obstructive pulmonary disease (COPD) affected an estimated 10.6% of the global population, translating to 480 million cases across both men and women. This chronic respiratory condition continues to expand as a major public health concern, with projections indicating a 23.3% increase in cases by 2050. By that time, the total number of COPD cases is expected to reach 592 million, representing 9.5% of the global at-risk population. Nasal vaccines are particularly effective in preventing respiratory diseases because they mimic the natural infection route of airborne viruses and bacteria. Countries with high infection rates are increasingly investing in preventive immunization strategies, thereby accelerating the adoption of nasal vaccine technologies.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the nasal vaccines market is navigating the complex regulatory landscape. The approval process for nasal vaccines can be more challenging compared to traditional injectable vaccines. Regulators need to ensure the safety and efficacy of these vaccines, which can lead to longer development timelines and higher costs. To address this challenge, collaboration between vaccine developers and regulatory agencies is essential to streamline the approval process and establish clear guidelines for nasal vaccine development.

Key Market Trends

Technological Advancements

The global healthcare landscape is constantly evolving, with technological advancements at the forefront of innovation. One significant development is the growing interest in nasal vaccines, a novel approach to immunization that offers numerous advantages over traditional injection-based vaccines. These advancements have ignited a surge in the Global Nasal Vaccines Market, shaping the future of preventive medicine and public health.

Advancements in vaccine formulation have played a pivotal role in the growth of nasal vaccines. Researchers are developing new formulations that enhance vaccine stability, improve antigen delivery, and minimize side effects, thereby increasing their efficacy and safety. Adjuvants are substances added to vaccines to boost the body's immune response. Recent developments in adjuvant technology have led to the creation of nasal vaccines that can trigger stronger and more durable immune responses, improving their overall effectiveness.

Key Market Players

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

Report Scope:

In this report, the Global Nasal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Vaccines Market, By Vaccine Type:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit
• Recombinant and Conjugate Vaccines
• Others

Nasal Vaccines Market, By Application:

• Influenza
• COVID-19
• Others

Nasal Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Nasal Vaccines Market.

Available Customizations:

Global Nasal Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Nasal Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant and Conjugate Vaccines, Others)
  • 5.2.2. By Application (Influenza, COVID-19, Others (such as Cholera, Typhoid, etc.))
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nasal Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nasal Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nasal Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nasal Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Application

7. Europe Nasal Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nasal Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Nasal Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Nasal Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Nasal Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nasal Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Nasal Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Nasal Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nasal Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nasal Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nasal Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nasal Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Application

9. South America Nasal Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Nasal Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Nasal Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Nasal Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Nasal Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Nasal Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Nasal Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Nasal Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Nasal Vaccines Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Vaxart, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. FluGen Inc.
• 14.3. Altimmune, Inc.
• 14.4. Sinovac Biotech Ltd.
• 14.5. Sanofi Pasteur SA
• 14.6. Pfizer Inc.
• 14.7. GlaxoSmithKline plc
• 14.8. Johnson & Johnson
• 14.9. Ennaid Therapeutics, LLC

15. Strategic Recommendations

16. About Us & Disclaimer